https://orcid.org/0000-0001-6732-4593
Figures & data
Figure 1 Study design.
Notes: aCOPD diagnosis between January 1, 2007 and December 31, 2016 and a spirometry record of FEV1/FVC <0.7 at any time. bNew inhaled maintenance therapy (or class) prescribed between January 1, 2014 and December 31, 2016 (index date). Patients were assessed for persistence on their newly prescribed therapy (without switches, additions or step-up/down) for 12 months post-index. cPatients had at least 12 months’ history available in the database prior to the index date. dFuture outcomes of interest were ascertained from the database 12 months post-index, up to December 31, 2017.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 1 Patient Demographics and Clinical Characteristics, Overall and by Maintenance Therapy Initiated
Table 2 Disease Burden in the 12-Month Post-Index Observation Period
Figure 2 Maintenance therapies prescribed at index.
Notes: Patients treated with ICS/LAMA (n = 92; 1.1%) are not included in this figure.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MITT, multiple-inhaler triple therapy.
Table 3 Exacerbation Events in the 12-Month Post-Index Observation Period
Figure 3 General practitioner visits in the 12-month post-index observation period.
Notes: Patients treated with LABA monotherapy (n = 165; 2.0%) and ICS/LAMA (n = 92; 1.1%) are not included in this figure. All variables were measured in the 12 months after initiation of inhaled maintenance therapy (index date). Percentages are based upon the number of patients (n) in each maintenance therapy group.
Abbreviations: GP, general practitioner; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MITT, multiple-inhaler triple therapy.
